B Cells in Oncology

Pero et al (2022) Diversification and shared features of tumor-binding antibody repertoires in tumor, sentinel lymph node and blood of three patients with breast cancer Clin Transl Immunology (https://doi.org/10.1002/cti2.1409)


Dowling et al, (2021) IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr LBA022. (https://doi.org/10.1158/1535-7163.TARG-21-LBA022)


Dowling et al (2022) IMM20059, a novel anti-EPN1 antibody, in combination with Atezolizumab, significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy SITC 37th Annual Meeting Journal of ImmunoTherapy of Cancer NOC 2022, 10 (Suppl 2) A859. (http://dx.doi.org/10.1136/jitc-2022-SITC2022.0823)



Nikitin et al, (2022) IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 Science Immunology (https://www.science.org/doi/epdf/10.1126/sciimmunol.abl9943)

DiMuzio et al, (2021) Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein, Vaccine X (https://doi.org/10.1016/j.jvacx.2021.100098)